NLS Pharmaceutics is a clinical‐stage biopharmaceutical company dedicated to the research and development of proprietary, cannabinoid‐based therapeutics targeting sleep disorders. Leveraging a novel platform for the modulation of the endocannabinoid system, the company focuses on creating differentiated pharmaceutical products designed to address unmet needs in conditions such as insomnia, narcolepsy, and hypersomnia. Its approach is grounded in preclinical validation and clinical studies that aim to establish safety, tolerability, and efficacy profiles distinct from existing therapies.
The company’s development pipeline includes multiple lead candidates, among them NP104, an oral formulation intended for the treatment of primary insomnia, and NP120, a nasal spray formulation for the management of narcolepsy and excessive daytime sleepiness. Each candidate is advanced through Phase II clinical trials, with endpoints tailored to demonstrate improvements in sleep architecture, daytime functioning, and quality of life. NLS Pharmaceutics also explores combination regimens to optimize therapeutic benefit and minimize adverse effects commonly associated with traditional sleep medications.
Founded in Switzerland, NLS Pharmaceutics operates research facilities in Zurich and conducts clinical trials across Europe and the United States. The company went public on the NASDAQ exchange in 2019, providing access to capital markets to support its clinical development and regulatory filings in major jurisdictions. NLS maintains collaborations with academic centers and specialty sleep clinics to advance its pipeline and gather real‐world evidence on patient outcomes.
At the helm of the organization is CEO Luigi Pollina, supported by a leadership team with deep experience in neuroscience, drug development, and regulatory affairs. The board and management bring together expertise in pharmaceutical R&D, clinical operations, and commercial strategy to guide NLS Pharmaceutics toward its goal of delivering novel, cannabinoid‐based treatments for sleep‐related disorders on a global scale.
AI Generated. May Contain Errors.
